Monday September 12, 2016 0 comments
WESTMINSTER -- Surefire Medical, Inc. today announced the German Institute of Medical Documentation and Information (DIMDI) has issued a unique classification code (OPS) for the Surefire Infusion System, which will allow the governmental organization to track and measure the use of Surefire technology in German hospitals.
The issuance of this code marks the first step to obtain a specific diagnosis-related group (DRG) code and the appropriate reimbursement for Surefire products in Germany, Surefire said.
The new OPS code – 8-83b.k – specifically calls out the use of a catheter-based infusion system with dynamic, expandable tip for selective embolization.
“This OPS code is a significant milestone for our commercialization efforts in Germany and to bringing our technology to market,” said James E. Chomas, Surefire’s CEO and president.
“We look forward to making further investment in the geography and taking the required steps to gain the appropriate DRG and reimbursement.”
Surefire said early clinical evidence being presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Congress this year shows the results of a multi-center registry in which the use of the Surefire Precision Infusion System to deliver therapy in the treatment of primary liver cancer (hepatocellular carcinoma or HCC) was associated with a 68 percent complete tumor response and 92 percent objective tumor response.